There were 1,783 press releases posted in the last 24 hours and 442,662 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image